RESEARCH-USE BIOSIMILAR ANTIBODY
Orilanolimab
Monoclonal antibody · IgG4
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity.
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity.
Orilanolimab is a recombinant research-use antibody directed against FCGRT.